Filing Flows › Comparisons › FDMT vs LENZ
4D Molecular Therapeutics vs Lenz Therapeutics: FDMT and LENZ compared
4D Molecular Therapeutics is the larger company: $3.8M of revenue in its latest quarter (Q2 2026) against $3.4M for Lenz Therapeutics (Q3 2026). 4D Molecular Therapeutics is growing faster (252× against -73% a year earlier).
Where the money goes: FDMT and LENZ
4D Molecular Therapeutics (FDMT) · Q2 2026
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart follows the revenue to costs, profit and cash.
Lenz Therapeutics (LENZ) · Q3 2026
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
| 4D Molecular Therapeutics (FDMT) | Lenz Therapeutics (LENZ) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $3.8M | $3.4M |
| Revenue growth, Y/Y | 252× | -73% |
| Operating margin | n/m | -972.8% |
| Net earnings | −$72.9M | −$31.0M |
| Net margin | — | -915.2% |
| Operating cash flow | −$70.0M | −$22.3M |
Where the revenue comes from
Lenz Therapeutics
- Product sales, net: $2.6M (77%)
- License revenue: $785K (23%)
Questions
Which is bigger, 4D Molecular Therapeutics or Lenz Therapeutics?
4D Molecular Therapeutics is the larger company: $3.8M of revenue in its latest quarter (Q2 2026) against $3.4M for Lenz Therapeutics (Q3 2026).
Is 4D Molecular Therapeutics or Lenz Therapeutics growing faster?
4D Molecular Therapeutics is growing faster (252× against -73% a year earlier).
More: 4D Molecular Therapeutics earnings · how 4D Molecular Therapeutics makes money · Lenz Therapeutics earnings · how Lenz Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.